Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hind Lal

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Cardiovascular Drugs and Therapy|July 23, 2017
Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et alManisha Gupte, Prachi Umbarkar, Hind Lal
Journal of the American College of Cardiology|January 19, 2013
Cancer genetics and the cardiotoxicity of the therapeuticsHind Lal, Kyle L Kolaja, Thomas Force
Cells|September 28, 2021
Mechanisms of Fibroblast Activation and Myocardial Fibrosis: Lessons Learned from FB-Specific Conditional Mouse ModelsPrachi Umbarkar, Suma Ejantkar, Sultan Tousif, et al.
Circulation Research|January 2, 2015
The GSK-3 family as therapeutic target for myocardial diseasesHind Lal, Firdos Ahmad, James Woodgett, et al.
Circulation Research|July 9, 2016
Response by Zhou et al to Letter Regarding Article, "Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy"Jibin Zhou, Firdos Ahmad, Hind Lal, et al.
The American Journal of Pathology|April 29, 2020
Mouse Models of Heart Failure with Preserved or Reduced Ejection FractionNatalie A Noll, Hind Lal, W David Merryman
Circulation Journal : Official Journal of the Japanese Circulation Society|June 6, 2014
Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac diseaseHind Lal, Firdos Ahmad, Shan Parikh, et al.
International Journal of Cardiology|May 30, 2020
Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinibAnand Prakash Singh, Prachi Umbarkar, Sultan Tousif, et al.
Genesis (New York, N.Y. : 2000)|March 29, 2019
Generation of Nppa-tagBFP reporter knock-in mouse line for studying cardiac chamber specificationZhentao Zhang, Qinkun Zhang, Hind Lal, et al.
Journal of Clinical Medicine|June 19, 2020
A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 MitigationAnand Prakash Singh, Sultan Tousif, Prachi Umbarkar, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Cardiovascular Drugs and Therapy|July 23, 2017
Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et alManisha Gupte, Prachi Umbarkar, Hind Lal
Journal of the American College of Cardiology|January 19, 2013
Cancer genetics and the cardiotoxicity of the therapeuticsHind Lal, Kyle L Kolaja, Thomas Force
Cells|September 28, 2021
Mechanisms of Fibroblast Activation and Myocardial Fibrosis: Lessons Learned from FB-Specific Conditional Mouse ModelsPrachi Umbarkar, Suma Ejantkar, Sultan Tousif, et al.
Circulation Research|January 2, 2015
The GSK-3 family as therapeutic target for myocardial diseasesHind Lal, Firdos Ahmad, James Woodgett, et al.
Circulation Research|July 9, 2016
Response by Zhou et al to Letter Regarding Article, "Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy"Jibin Zhou, Firdos Ahmad, Hind Lal, et al.
The American Journal of Pathology|April 29, 2020
Mouse Models of Heart Failure with Preserved or Reduced Ejection FractionNatalie A Noll, Hind Lal, W David Merryman
Circulation Journal : Official Journal of the Japanese Circulation Society|June 6, 2014
Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac diseaseHind Lal, Firdos Ahmad, Shan Parikh, et al.
International Journal of Cardiology|May 30, 2020
Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinibAnand Prakash Singh, Prachi Umbarkar, Sultan Tousif, et al.
Genesis (New York, N.Y. : 2000)|March 29, 2019
Generation of Nppa-tagBFP reporter knock-in mouse line for studying cardiac chamber specificationZhentao Zhang, Qinkun Zhang, Hind Lal, et al.
Journal of Clinical Medicine|June 19, 2020
A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 MitigationAnand Prakash Singh, Sultan Tousif, Prachi Umbarkar, et al.
Pageof 7